Vasopressin
Description
Name: Vasopressin
Type: biotech
Groups: approved
Indication: For the treatment of enuresis, polyuria, diabetes insipidus, polydipsia and oesophageal varices with bleeding
Accession Number: DB00067 ( BIOD00110, BTD00110)
Description: Antidiuretic hormone, also known as vasopressin, is a nine amino acid peptide secreted from the posterior pituitary. Antidiuretic hormone binds to receptors in the distal or collecting tubules of the kidney and promotes reabsorbtion of water back into the circulation
Structure:
Prescription Products:
Generic Prescription Products: Not Available
Over the Counter Products: Not Available
Prescription Products:
International Brands
Brand Names
Brand Mixtures
Categories
Type: biotech
Groups: approved
Indication: For the treatment of enuresis, polyuria, diabetes insipidus, polydipsia and oesophageal varices with bleeding
Accession Number: DB00067 ( BIOD00110, BTD00110)
Description: Antidiuretic hormone, also known as vasopressin, is a nine amino acid peptide secreted from the posterior pituitary. Antidiuretic hormone binds to receptors in the distal or collecting tubules of the kidney and promotes reabsorbtion of water back into the circulation
Structure:
Prescription Products:
| Name | Dosage | Strength | Route | Marketing Start | Marketing End | Country |
| Pitressin | injection | 20 [USP'U]/mL | intramuscular; subcutaneous | 01-10-2007 | US | |
| Pitressin Inj 10 Unit/0.5ml | liquid | 10 unit | intramuscular; subcutaneous | 31-12-1971 | 25-08-1997 | Canada |
| Pressyn Ar | liquid | 20 unit | intramuscular; subcutaneous | 04-11-2002 | Canada | |
| Vasopressin | injection, solution | 20 [USP'U]/mL | intramuscular; subcutaneous | 15-08-1996 | US | |
| Vasopressin | injection, solution | 20 [USP'U]/mL | intramuscular; subcutaneous | 01-10-1992 | US | |
| Vasopressin | injection, solution | 20 [USP'U]/mL | intramuscular; subcutaneous | 01-08-2010 | US | |
| Vasopressin | injection, solution | 20 [USP'U]/mL | intramuscular; subcutaneous | 01-10-1992 | US | |
| Vasopressin | injection, solution | 20 [USP'U]/mL | intramuscular; subcutaneous | 01-03-2010 | US | |
| Vasopressin | injection, solution | 20 [USP'U]/mL | intramuscular; subcutaneous | 17-07-2001 | US | |
| Vasopressin | injection, solution | 20 [USP'U]/mL | intramuscular; subcutaneous | 17-12-2013 | US | |
| Vasopressin | injection | 20 [USP'U]/mL | intramuscular | 17-10-2011 | US | |
| Vasopressin Inj 20unit/ml USP | liquid | 20 unit | intramuscular; nasal; subcutaneous | 31-12-1988 | 22-07-2015 | Canada |
| Vasopressin Inj 20unit/ml USP | liquid | 20 unit | intramuscular; subcutaneous | 31-12-1992 | 10-09-1996 | Canada |
| Vasopressin Injection | solution | 20 unit | intramuscular; subcutaneous | 14-08-1996 | Canada | |
| Vasopressin Injection USP | solution | 20 unit | intramuscular; subcutaneous | 10-12-2003 | Canada |
Generic Prescription Products: Not Available
Over the Counter Products: Not Available
Prescription Products:
| Name | Dosage | Strength | Route | Marketing Start | Marketing End | Country |
| Pitressin | injection | 20 [USP'U]/mL | intramuscular; subcutaneous | 01-10-2007 | US | |
| Pitressin Inj 10 Unit/0.5ml | liquid | 10 unit | intramuscular; subcutaneous | 31-12-1971 | 25-08-1997 | Canada |
| Pressyn Ar | liquid | 20 unit | intramuscular; subcutaneous | 04-11-2002 | Canada | |
| Vasopressin | injection, solution | 20 [USP'U]/mL | intramuscular; subcutaneous | 15-08-1996 | US | |
| Vasopressin | injection, solution | 20 [USP'U]/mL | intramuscular; subcutaneous | 01-10-1992 | US | |
| Vasopressin | injection, solution | 20 [USP'U]/mL | intramuscular; subcutaneous | 01-08-2010 | US | |
| Vasopressin | injection, solution | 20 [USP'U]/mL | intramuscular; subcutaneous | 01-10-1992 | US | |
| Vasopressin | injection, solution | 20 [USP'U]/mL | intramuscular; subcutaneous | 01-03-2010 | US | |
| Vasopressin | injection, solution | 20 [USP'U]/mL | intramuscular; subcutaneous | 17-07-2001 | US | |
| Vasopressin | injection, solution | 20 [USP'U]/mL | intramuscular; subcutaneous | 17-12-2013 | US | |
| Vasopressin | injection | 20 [USP'U]/mL | intramuscular | 17-10-2011 | US | |
| Vasopressin Inj 20unit/ml USP | liquid | 20 unit | intramuscular; nasal; subcutaneous | 31-12-1988 | 22-07-2015 | Canada |
| Vasopressin Inj 20unit/ml USP | liquid | 20 unit | intramuscular; subcutaneous | 31-12-1992 | 10-09-1996 | Canada |
| Vasopressin Injection | solution | 20 unit | intramuscular; subcutaneous | 14-08-1996 | Canada | |
| Vasopressin Injection USP | solution | 20 unit | intramuscular; subcutaneous | 10-12-2003 | Canada |
International Brands
- No Brands
Brand Names
- No Brands
Brand Mixtures
| Brand Name | Ingredients |
|---|---|
| Vasopressin | Vasopressin |
| Vasopressin | Vasopressin |
| Vasopressin | Vasopressin |
| Vasopressin | Vasopressin |
| Vasopressin | Vasopressin |
| Vasopressin | Vasopressin |
| Vasopressin | Vasopressin |
| Pitressin | Vasopressin |
| Vasopressin | Vasopressin |
| Pressyn Ar | Vasopressin |
| Vasopressin Injection USP | Vasopressin |
| Pitressin Inj 10 Unit/0.5ml | Vasopressin |
| Vasopressin Inj 20unit/ml USP | Vasopressin |
| Vasopressin Inj 20unit/ml USP | Vasopressin |
| Vasopressin Injection | Vasopressin |
| Brand Name | Ingredients |
|---|---|
| Vasopressin | Vasopressin |
| Vasopressin | Vasopressin |
| Vasopressin | Vasopressin |
| Vasopressin | Vasopressin |
| Vasopressin | Vasopressin |
| Vasopressin | Vasopressin |
| Vasopressin | Vasopressin |
| Pitressin | Vasopressin |
| Vasopressin | Vasopressin |
| Pressyn Ar | Vasopressin |
| Vasopressin Injection USP | Vasopressin |
| Pitressin Inj 10 Unit/0.5ml | Vasopressin |
| Vasopressin Inj 20unit/ml USP | Vasopressin |
| Vasopressin Inj 20unit/ml USP | Vasopressin |
| Vasopressin Injection | Vasopressin |
Categories
- Antidiuretic Agents
Pharmacology
Indication: For the treatment of enuresis, polyuria, diabetes insipidus, polydipsia and oesophageal varices with bleeding
Pharmacodynamics: Not Available
Mechanism of action: Vasopressin acts on three different receptors, vasopressin receptor V1a (which initiates vasoconstriction, liver gluconeogenesis, platelet aggregation and release of factor VIII), vasopressin receptor V1b (which mediates corticotrophin secretion from the pituitary) and vasopressin receptor V2 which controls free water reabsorption in the renal medullar. The binding of vasopressin to the V2 receptor activates adenylate cyclase which causes the release of aquaporin 2 channels into the cells lining the renal medullar duct. This allows water to be reabsorbed down an osmotic gradient so the urine is more concentrated.
Absorption: Not Available
Volume of distribution: Not Available
Protein binding: 1%
Metabolism: Not Available
Route of elimination: Not Available
Half life: 10-20 minutes
Clearance: Not Available
Toxicity: Not Available
Affected organisms
SNP Mediated Adverse Drug Reactions
Pharmacodynamics: Not Available
Mechanism of action: Vasopressin acts on three different receptors, vasopressin receptor V1a (which initiates vasoconstriction, liver gluconeogenesis, platelet aggregation and release of factor VIII), vasopressin receptor V1b (which mediates corticotrophin secretion from the pituitary) and vasopressin receptor V2 which controls free water reabsorption in the renal medullar. The binding of vasopressin to the V2 receptor activates adenylate cyclase which causes the release of aquaporin 2 channels into the cells lining the renal medullar duct. This allows water to be reabsorbed down an osmotic gradient so the urine is more concentrated.
Absorption: Not Available
Volume of distribution: Not Available
Protein binding: 1%
Metabolism: Not Available
Route of elimination: Not Available
Half life: 10-20 minutes
Clearance: Not Available
Toxicity: Not Available
Affected organisms
- Not Available
SNP Mediated Adverse Drug Reactions
- Not Available
Pharmacoeconomics
Manufacturers:
Packagers:
Dosage forms
Prices
Patents
- Parke davis div warner lambert co
Packagers:
- American Regent
- APP Pharmaceuticals
- APPD
- A-S Medication Solutions LLC
- Cardinal Health
- JHP Pharmaceuticals LLC
- Luitpold Pharmaceuticals Inc.
- Monarch Pharmacy
- PD-Rx Pharmaceuticals Inc.
Dosage forms
| Form | Route | Strength |
|---|---|---|
| Injection | intramuscular; subcutaneous | 20 [USP'U]/mL |
| Liquid | intramuscular; subcutaneous | 10 unit |
| Liquid | intramuscular; subcutaneous | 20 unit |
| Injection | intramuscular | 20 [USP'U]/mL |
| Injection, solution | intramuscular; subcutaneous | 20 [USP'U]/mL |
| Liquid | intramuscular; nasal; subcutaneous | 20 unit |
| Solution | intramuscular; subcutaneous | 20 unit |
| Form | Route | Strength |
|---|---|---|
| Injection | intramuscular; subcutaneous | 20 [USP'U]/mL |
| Liquid | intramuscular; subcutaneous | 10 unit |
| Liquid | intramuscular; subcutaneous | 20 unit |
| Injection | intramuscular | 20 [USP'U]/mL |
| Injection, solution | intramuscular; subcutaneous | 20 [USP'U]/mL |
| Liquid | intramuscular; nasal; subcutaneous | 20 unit |
| Solution | intramuscular; subcutaneous | 20 unit |
Prices
| Unit description | Cost | Unit |
|---|---|---|
| Vasopressin 20 unit/ml vial | $1.86 | ml |
| Vasopressin 10 unit/0.5 ml vial | $2.88 | vial |
| Pitressin 20 unit/ml vial | $7.68 | ml |
| Unit description | Cost | Unit |
|---|---|---|
| Vasopressin 20 unit/ml vial | $1.86 | ml |
| Vasopressin 10 unit/0.5 ml vial | $2.88 | vial |
| Pitressin 20 unit/ml vial | $7.68 | ml |
Patents
| Country | Patent Number | Approved | Expires (estimated) |
|---|
Interactions
Drug Interactions
Food Interactions:
| Drug | Interaction |
|---|
| Drug | Interaction |
|---|
Food Interactions:
- Ethanol
Taxonomy
Kingdom: Organic Compounds
Super Class: Not Available
Class: Not Available
Sub Class: Not Available
Direct Parent: Not Available
Alternative Parents:
substituent:
Super Class: Not Available
Class: Not Available
Sub Class: Not Available
Direct Parent: Not Available
Alternative Parents:
- Not Available
substituent:
- Not Available
References
Synthesis Reference: Nedumparambil A. Abraham, Hans U. Immer, Kazimir Sestanj, "Process for producing triglycyl-lysine vasopressin and intermediates therefor." U.S. Patent US4093610, issued June, 1963.
General Reference: # Bielsky IF, Hu SB, Szegda KL, Westphal H, Young LJ: Profound impairment in social recognition and reduction in anxiety-like behavior in vasopressin V1a receptor knockout mice. Neuropsychopharmacology. 2004 Mar;29(3):483-93. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14647484 # Wersinger SR, Caldwell HK, Martinez L, Gold P, Hu SB, Young WS 3rd: Vasopressin 1a receptor knockout mice have a subtle olfactory deficit but normal aggression. Genes Brain Behav. 2007 Aug;6(6):540-51. Epub 2006 Nov 3. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17083331 # Lolait SJ, Stewart LQ, Jessop DS, Young WS 3rd, O'Carroll AM: The hypothalamic-pituitary-adrenal axis response to stress in mice lacking functional vasopressin V1b receptors. Endocrinology. 2007 Feb;148(2):849-56. Epub 2006 Nov 22. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17122081 # Wersinger SR, Kelliher KR, Zufall F, Lolait SJ, O'Carroll AM, Young WS 3rd: Social motivation is reduced in vasopressin 1b receptor null mice despite normal performance in an olfactory discrimination task. Horm Behav. 2004 Dec;46(5):638-45. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15555506 # Kanwar S, Woodman RC, Poon MC, Murohara T, Lefer AM, Davenpeck KL, Kubes P: Desmopressin induces endothelial P-selectin expression and leukocyte rolling in postcapillary venules. Blood. 1995 Oct 1;86(7):2760-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/7545469
External Links:
ATC Codes:
AHFS Codes:
MSDS: Download
General Reference: # Bielsky IF, Hu SB, Szegda KL, Westphal H, Young LJ: Profound impairment in social recognition and reduction in anxiety-like behavior in vasopressin V1a receptor knockout mice. Neuropsychopharmacology. 2004 Mar;29(3):483-93. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14647484 # Wersinger SR, Caldwell HK, Martinez L, Gold P, Hu SB, Young WS 3rd: Vasopressin 1a receptor knockout mice have a subtle olfactory deficit but normal aggression. Genes Brain Behav. 2007 Aug;6(6):540-51. Epub 2006 Nov 3. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17083331 # Lolait SJ, Stewart LQ, Jessop DS, Young WS 3rd, O'Carroll AM: The hypothalamic-pituitary-adrenal axis response to stress in mice lacking functional vasopressin V1b receptors. Endocrinology. 2007 Feb;148(2):849-56. Epub 2006 Nov 22. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17122081 # Wersinger SR, Kelliher KR, Zufall F, Lolait SJ, O'Carroll AM, Young WS 3rd: Social motivation is reduced in vasopressin 1b receptor null mice despite normal performance in an olfactory discrimination task. Horm Behav. 2004 Dec;46(5):638-45. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15555506 # Kanwar S, Woodman RC, Poon MC, Murohara T, Lefer AM, Davenpeck KL, Kubes P: Desmopressin induces endothelial P-selectin expression and leukocyte rolling in postcapillary venules. Blood. 1995 Oct 1;86(7):2760-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/7545469
External Links:
| Resource | Link |
|---|---|
| RxList | http://www.rxlist.com/cgi/generic3/vasopressin.htm |
| Drugs.com | http://www.drugs.com/mtm/vasopressin.html |
| Resource | Link |
|---|---|
| RxList | http://www.rxlist.com/cgi/generic3/vasopressin.htm |
| Drugs.com | http://www.drugs.com/mtm/vasopressin.html |
ATC Codes:
- Array
AHFS Codes:
- 68:28.00
MSDS: Download